本文言語 | English |
---|---|
ページ(範囲) | 9-10 |
ページ数 | 2 |
ジャーナル | Annals of Surgical Oncology |
巻 | 28 |
号 | 1 |
DOI |
|
出版ステータス | Published - 2021 1月 |
ASJC Scopus subject areas
- 外科
- 腫瘍学
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Surgical Oncology, Vol. 28, No. 1, 01.2021, p. 9-10.
研究成果: Comment/debate › 査読
}
TY - JOUR
T1 - The Potential of Lymph Node Yield as a Quality Indicator of Esophagectomy for Esophageal Cancer
AU - Matsuda, Satoru
AU - Kitagawa, Yuko
N1 - Funding Information: Yuko Kitagawa received lecture fees from Asahi Kasei Co, Ltd; Taiho Pharmaceutical Company, Ltd; Chugai Pharmaceutical Company, Ltd; EA Pharma Company, Ltd; Yakult Honsha Company, Ltd; Otsuka Pharmaceutical Company, Ltd; Otsuka Pharmaceutical Factory Inc, Shionogi & Company, Ltd; Astellas Pharma, Inc; Dainippon Sumitomo Pharma Company, Ltd; Taisho Toyama Pharmaceutical Company; Ono Pharmaceutical Company; Nihon Pharmaceutical Co, Ltd; Sanofi K.K., Eisai Company, Ltd; and Kaken Pharmaceutical Company, Ltd. Yuko Kitagawa received Grants for research expenses and scholarship from Taiho Pharmaceutical Company, Ltd; Chugai Pharmaceutical Company, Ltd; Yakult Honsha Company, Ltd; Daiichi Sankyo Company, Ltd; Merck Serono Company, Ltd; Asahi Kasei Company, Ltd; EA Pharma Company, Ltd; Otsuka Pharmaceutical Company, Ltd; Takeda Pharmaceutical Company, Ltd; Otsuka Pharmaceutical Factory, Inc; Shionogi Company, Ltd; Kaken Pharmaceutical Company, Ltd; Kowa Pharmaceutical Company, Ltd; Astellas Pharma, Inc; Medicon, Inc; Dainippon Sumitomo Pharma Company, Ltd; Taisho Toyama Pharmaceutical Company, Ltd; Kyouwa Hakkou Kirin Company, Ltd; Pfizer Japan, Inc; Ono Pharmaceutical Company, Ltd; Nihon Pharmaceutical Company, Ltd; Japan Blood Products Organization Medtronic Japan Company, Ltd; Sanofi K.K., Eisai Company, Ltd; Tsumura & Company, Ltd; KCI Licensing, Inc; Abbott Japan Company, Ltd; and Fujifilm, Toyama Chemical Company, Ltd. Yuko Kitagawa worked as a director of endowed chair supported from Taiho Pharmaceutical Company, Ltd; and Chugai Pharmaceutical Company, Ltd. Satoru Matsuda has no conflicts of interest.
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85092638212&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092638212&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-09146-6
DO - 10.1245/s10434-020-09146-6
M3 - Comment/debate
C2 - 33063260
AN - SCOPUS:85092638212
SN - 1068-9265
VL - 28
SP - 9
EP - 10
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 1
ER -